Astellas to bring OSI fully into the fold by mid-2011
This article was originally published in Scrip
Astellas expects to complete the integration of its US acquisition OSI Pharmaceuticals by the end of June next year, by which time a number of restructuring moves associated with the transaction will have taken place.
You may also be interested in...
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.